Key points are not available for this paper at this time.
Introduction 0.01) and lower TIR (p0.05). TIR evolution across the 3rd trimester differed in the presence vs. absence of HDP (p0.05; Figure), with greatest interaction at 28°-316 weeks. Evolution of all metrics differed in the presence vs. absence of RDS (p0.05), with greatest interaction at 28°-336 weeks. Conclusion: The early 3rd trimester, a period of peak insulin resistance, is a critical window to optimize CGM metrics to mitigate APO risk. Disclosure S.A. Fisher: None. M.F. Villa Tamayo: Research Support; Dexcom, Inc. J. Pavan: Other Relationship; Dexcom, Inc. M. Moscoso-Vasquez: Research Support; Dexcom, Inc. Other Relationship; Dexcom, Inc. C. Fabris: Research Support; Novo Nordisk A/S. Other Relationship; Novo Nordisk A/S, Dexcom, Inc. N. Conboy: None. C.M. Niznik: None. L.D. Yee: None. M.A. Kohn: None. E. Kobayashi: None. A.R. Majithia: None. J. Huang: None. T. Tian: None. R. Aaron: None. D.C. Klonoff: Consultant; Afon Technology Ltd, Better Therapeutics, Inc, Glucotrack, LIfecare, Nevro Corp., Novo Nordisk, Samsung, Thirdwayv Inc.
Fisher et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: